全文获取类型
收费全文 | 28113篇 |
免费 | 1467篇 |
国内免费 | 337篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 1124篇 |
妇产科学 | 242篇 |
基础医学 | 1676篇 |
口腔科学 | 21篇 |
临床医学 | 4140篇 |
内科学 | 6816篇 |
皮肤病学 | 59篇 |
神经病学 | 589篇 |
特种医学 | 2214篇 |
外国民族医学 | 1篇 |
外科学 | 2571篇 |
综合类 | 5037篇 |
预防医学 | 1706篇 |
眼科学 | 22篇 |
药学 | 2268篇 |
26篇 | |
中国医学 | 644篇 |
肿瘤学 | 709篇 |
出版年
2024年 | 18篇 |
2023年 | 335篇 |
2022年 | 761篇 |
2021年 | 954篇 |
2020年 | 937篇 |
2019年 | 725篇 |
2018年 | 791篇 |
2017年 | 781篇 |
2016年 | 859篇 |
2015年 | 888篇 |
2014年 | 2014篇 |
2013年 | 1853篇 |
2012年 | 1837篇 |
2011年 | 1871篇 |
2010年 | 1548篇 |
2009年 | 1479篇 |
2008年 | 1480篇 |
2007年 | 1575篇 |
2006年 | 1402篇 |
2005年 | 1185篇 |
2004年 | 907篇 |
2003年 | 745篇 |
2002年 | 538篇 |
2001年 | 570篇 |
2000年 | 457篇 |
1999年 | 421篇 |
1998年 | 352篇 |
1997年 | 315篇 |
1996年 | 234篇 |
1995年 | 275篇 |
1994年 | 238篇 |
1993年 | 167篇 |
1992年 | 167篇 |
1991年 | 130篇 |
1990年 | 135篇 |
1989年 | 118篇 |
1988年 | 115篇 |
1987年 | 104篇 |
1986年 | 74篇 |
1985年 | 87篇 |
1984年 | 91篇 |
1983年 | 25篇 |
1982年 | 77篇 |
1981年 | 52篇 |
1980年 | 38篇 |
1979年 | 51篇 |
1978年 | 36篇 |
1977年 | 35篇 |
1976年 | 25篇 |
1974年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Revista portuguesa de cardiologia》2022,41(9):783-789
Amiodarone is the most potent antiarrhythmic drug available and is commonly prescribed to treat and prevent not only life-threatening ventricular arrhythmias but also atrial fibrillation (AF). The latest European Society of Cardiology AF guidelines state that amiodarone is recommended for long-term rhythm control in all AF patients but that other antiarrhythmic drugs should be considered first whenever possible, due to its extracardiac toxicity. In patients without significant or with only minimal structural heart disease, amiodarone is not listed as a possibility in their therapeutic scheme. Still, amiodarone is widely and liberally used, and is the most prescribed antiarrhythmic drug for patients with AF despite its high toxicity profile. Non-cardiovascular death was more frequent with amiodarone treatment than with a rate control strategy in AFFIRM, while meta-analyses suggest an association between amiodarone use in patients without structural heart disease and increased non-cardiovascular mortality. Severe or even fatal outcomes due to amiodarone may occur years after treatment initiation and are often not acknowledged by the prescribing physician, who may no longer be following the patient. The lack of widely accepted diagnostic criteria and symptom definitions may lead to underestimation of the incidence of severe side effects and of its toxicity. Unlike the underestimated risk of toxicity with amiodarone, severe complications associated with catheter ablation are usually directly ascribed to the treatment even by non-medical personnel, possibly resulting in overestimation of risks. This brief review will address the issue of amiodarone overuse and the frequent underestimation of its toxicity, while suggesting scenarios in which its use is entirely reasonable, and compare it with catheter ablation. 相似文献
2.
3.
4.
5.
6.
9.
10.
《Mayo Clinic proceedings. Mayo Clinic》2022,97(8):1525-1533
The importance of the left atrial appendage (LAA) as the source of thromboembolism including stroke in patients with nonvalvular atrial fibrillation is well documented, with more than 90% of ischemic strokes related to a LAA thrombus. Although oral anticoagulation has been the standard of care, approximately 50% to 60% of patients either have contraindications to oral anticoagulation or do not continue the medication beyond the first year. This led to the development of local site-specific therapy to occlude the LAA by either surgical or transcatheter means. Despite marked advancements, incomplete LAA closure with surgical and transcatheter approaches remains frequent. The etiology of incomplete LAA closure and its clinical implications remain unclear. Multiple strategies are in development including changes in deployment techniques, a new device design, and alternative approaches to leak closure. 相似文献